Table 2.
Gene | Chromosome | MOI | LD | OOCM | PCMS (%)a |
---|---|---|---|---|---|
AGRN | 1p36.33 | AR | post | con, inf | < 1 |
ALG2 | 9q22.33 | AR | glyc | con, inf | < 1 |
ALG14 | 1p21.3 | AR | glyc | con, child | < 1 |
CHAT | 10q11.23 | AR | pre | con, inf | 4–5 |
CHRNA1 | 2q31.1 | AD/AR | post | con, adult | < 1 |
CHRNB1 | 17p13.1 | AF/AR | post | inf | < 1 |
CHRND | 2q37.1 | AD/AR | post | inf | < 1 |
CHRNE | 17p13.2 | AD/AR | post | con, inf, child, adult | 50 |
CHRNG | 2q37.1 | AR | post | con | uk |
COL13A1 | 10q22.1 | AR | post | con | < 1 |
COLQ | 3p24.2 | AR | syn | con, inf, child | 10–15 |
DOK7 | 4p16.3 | AR | post | con, inf, child, adol, adult | 10–15 |
DPAGT1 | 11q23.3 | AR | glyc | inf, adol | < 1 |
GFPT1 | 2p13.3 | AR | glyc | con, inf, child, adult | 2 |
GMPPB | 3p21.31 | AR | glyc | con | < 1 |
LAMA5 | 20q13.33 | uk | pre | con | < 1 |
LAMB2 | 3p21.31 | AR | syn | con | < 1 |
LRP4 | 11p11.2 | AR | post | con | < 1 |
MUNC13–1 | 19 | AR | pre | inf | < 1 |
MUSK | 9q31.3 | AR | post | con | < 1 |
MYO9A | 15q23 | AR | post | con | < 1 |
PLEC | 8q24.3 | AR | post | con | < 1 |
PREP1 | 2p21 | AR | post | con | < 1 |
RAPSN | 11p13-q1 | AR | post | con, inf, child, adol, adult | 10–20 |
SCN4A | 17q23.3 | AR | post | inf | < 1 |
SLC18A3 | 10q11.23 | AR | pre | con, inf | < 1 |
SLC25A1 | 22q11.21 | AR | post | inf | < 1 |
SLC5A7 | 2q12.3 | AD | pre | con, inf | < 1 |
SNAP25 | 20p12.2 | AD | pre | con | < 1 |
SYB1 | 12p | uk | pre | inf | < 1 |
SYT2 | 1q32.1 | AD | pre | child | < 1 |
VAMP1 | 12p13.21 | AR | pre | con | < 1 |
MOI mode of inheritance, LD localisation of defect, pre: presynaptic, syn: synaptic, post: post-synaptic, glyc: glycosylation defect, OOCM onset of clinical manifestations, con congenital, inf infantile, child childhood, adol adolescence, adult: adulthood PCMS prevalence of various subtypes, a: according to [6], uk unknown